Article Text

Download PDFPDF
Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy

Statistics from Altmetric.com

Footnotes

  • Contributors OL, the corresponding author, states that all the authors listed have contributed to the work.

  • Funding LA: research funding: Novartis, Pfizer.

  • Competing interests Honoraria: SC for Bristol-Myers Squibb, Janssen, Merck Sharp & Dohme and Roche. LA for Novartis, Pfizer, BMS, Sanofi and Ipsen. OL for Merck Sharp Dohme and Genzyme.

  • Ethics approval Gustave Roussy ethical committee.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • i Registre des Effets Indésirables Sévères des Anticorps Monoclonaux Immunomodulateurs en Cancérologie.